世界の多発性骨髄腫用モノクローナル抗体市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Monoclonal Antibody for Multiple Myeloma Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12480 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、多発性骨髄腫用モノクローナル抗体のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。多発性骨髄腫用モノクローナル抗体の種類別市場規模（エロツズマブ、ダラツズマブ、シルツキシマブ、ダセツズマブ、リツキシマブ、その他）、用途別市場規模（病院、ドラッグセンター、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・多発性骨髄腫用モノクローナル抗体の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Bristol Myers Squibb、Abbvie、Janssen Biotech、Karyopharm Therapeutics、PDL BioPharma、Roche、Seattle Genetics ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：エロツズマブ、ダラツズマブ、シルツキシマブ、ダセツズマブ、リツキシマブ、その他 ・用途別分析2016年-2026年：病院、ドラッグセンター、クリニック、その他 ・多発性骨髄腫用モノクローナル抗体の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・多発性骨髄腫用モノクローナル抗体のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・多発性骨髄腫用モノクローナル抗体のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・多発性骨髄腫用モノクローナル抗体の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・多発性骨髄腫用モノクローナル抗体の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Monoclonal Antibody for Multiple Myeloma market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Monoclonal Antibody for Multiple Myeloma size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Monoclonal Antibody for Multiple Myeloma market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Monoclonal Antibody for Multiple Myeloma market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Elotuzumab
Daratumumab
Siltuximab
Dacetuzumab
Rituximab
Other

Market segment by Application, can be divided into
Hospital
Drug Center
Clinic
Other

Market segment by players, this report covers
Bristol Myers Squibb
Abbvie
Janssen Biotech
Karyopharm Therapeutics
PDL BioPharma
Roche
Seattle Genetics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Monoclonal Antibody for Multiple Myeloma
1.2 Classification of Monoclonal Antibody for Multiple Myeloma by Type
1.2.1 Overview: Global Monoclonal Antibody for Multiple Myeloma Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Type in 2020
1.2.3 Elotuzumab
1.2.4 Daratumumab
1.2.5 Siltuximab
1.2.6 Dacetuzumab
1.2.7 Rituximab
1.2.8 Other
1.3 Global Monoclonal Antibody for Multiple Myeloma Market by Application
1.3.1 Overview: Global Monoclonal Antibody for Multiple Myeloma Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Other
1.4 Global Monoclonal Antibody for Multiple Myeloma Market Size & Forecast
1.5 Global Monoclonal Antibody for Multiple Myeloma Market Size and Forecast by Region
1.5.1 Global Monoclonal Antibody for Multiple Myeloma Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Monoclonal Antibody for Multiple Myeloma Market Size by Region, (2016-2021)
1.5.3 North America Monoclonal Antibody for Multiple Myeloma Market Size and Prospect (2016-2026)
1.5.4 Europe Monoclonal Antibody for Multiple Myeloma Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size and Prospect (2016-2026)
1.5.6 South America Monoclonal Antibody for Multiple Myeloma Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Monoclonal Antibody for Multiple Myeloma Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Monoclonal Antibody for Multiple Myeloma Market Drivers
1.6.2 Monoclonal Antibody for Multiple Myeloma Market Restraints
1.6.3 Monoclonal Antibody for Multiple Myeloma Trends Analysis
2 Company Profiles
2.1 Bristol Myers Squibb
2.1.1 Bristol Myers Squibb Details
2.1.2 Bristol Myers Squibb Major Business
2.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Product and Solutions
2.1.4 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Bristol Myers Squibb Recent Developments and Future Plans
2.2 Abbvie
2.2.1 Abbvie Details
2.2.2 Abbvie Major Business
2.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Product and Solutions
2.2.4 Abbvie Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Abbvie Recent Developments and Future Plans
2.3 Janssen Biotech
2.3.1 Janssen Biotech Details
2.3.2 Janssen Biotech Major Business
2.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Product and Solutions
2.3.4 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Janssen Biotech Recent Developments and Future Plans
2.4 Karyopharm Therapeutics
2.4.1 Karyopharm Therapeutics Details
2.4.2 Karyopharm Therapeutics Major Business
2.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Product and Solutions
2.4.4 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Karyopharm Therapeutics Recent Developments and Future Plans
2.5 PDL BioPharma
2.5.1 PDL BioPharma Details
2.5.2 PDL BioPharma Major Business
2.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Product and Solutions
2.5.4 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 PDL BioPharma Recent Developments and Future Plans
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche Monoclonal Antibody for Multiple Myeloma Product and Solutions
2.6.4 Roche Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Roche Recent Developments and Future Plans
2.7 Seattle Genetics
2.7.1 Seattle Genetics Details
2.7.2 Seattle Genetics Major Business
2.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Product and Solutions
2.7.4 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Seattle Genetics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Monoclonal Antibody for Multiple Myeloma Players Market Share
3.2.2 Top 10 Monoclonal Antibody for Multiple Myeloma Players Market Share
3.2.3 Market Competition Trend
3.3 Monoclonal Antibody for Multiple Myeloma Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Market Share by Type (2016-2021)
4.2 Global Monoclonal Antibody for Multiple Myeloma Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application (2016-2021)
5.2 Monoclonal Antibody for Multiple Myeloma Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2026)
6.2 North America Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2026)
6.3 North America Monoclonal Antibody for Multiple Myeloma Market Size by Country
6.3.1 North America Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2026)
6.3.2 United States Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
6.3.3 Canada Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
6.3.4 Mexico Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2026)
7.2 Europe Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2026)
7.3 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country
7.3.1 Europe Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2026)
7.3.2 Germany Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
7.3.3 France Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
7.3.5 Russia Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
7.3.6 Italy Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2026)
8.2 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2026)
8.3 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region
8.3.1 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Region (2016-2026)
8.3.2 China Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
8.3.3 Japan Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
8.3.4 South Korea Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
8.3.5 India Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
8.3.7 Australia Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2026)
9.2 South America Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2026)
9.3 South America Monoclonal Antibody for Multiple Myeloma Market Size by Country
9.3.1 South America Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2026)
9.3.2 Brazil Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
9.3.3 Argentina Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2026)
10.2 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2026)
10.3 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country
10.3.1 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2026)
10.3.2 Turkey Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
10.3.4 UAE Monoclonal Antibody for Multiple Myeloma Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Monoclonal Antibody for Multiple Myeloma Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Monoclonal Antibody for Multiple Myeloma Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) by Region (2016-2021)
Table 5. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Region (2021-2026)
Table 6. Bristol Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 7. Bristol Myers Squibb Major Business
Table 8. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Product and Solutions
Table 9. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Abbvie Corporate Information, Head Office, and Major Competitors
Table 11. Abbvie Major Business
Table 12. Abbvie Monoclonal Antibody for Multiple Myeloma Product and Solutions
Table 13. Abbvie Monoclonal Antibody for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Janssen Biotech Corporate Information, Head Office, and Major Competitors
Table 15. Janssen Biotech Major Business
Table 16. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Product and Solutions
Table 17. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Karyopharm Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. Karyopharm Therapeutics Major Business
Table 20. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Product and Solutions
Table 21. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. PDL BioPharma Corporate Information, Head Office, and Major Competitors
Table 23. PDL BioPharma Major Business
Table 24. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Product and Solutions
Table 25. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Roche Corporate Information, Head Office, and Major Competitors
Table 27. Roche Major Business
Table 28. Roche Monoclonal Antibody for Multiple Myeloma Product and Solutions
Table 29. Roche Monoclonal Antibody for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Seattle Genetics Corporate Information, Head Office, and Major Competitors
Table 31. Seattle Genetics Major Business
Table 32. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Product and Solutions
Table 33. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Global Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) by Players (2019-2021)
Table 35. Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Players (2019-2021)
Table 36. Breakdown of Monoclonal Antibody for Multiple Myeloma by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Monoclonal Antibody for Multiple Myeloma Players Head Office, Products and Services Provided
Table 38. Monoclonal Antibody for Multiple Myeloma Mergers & Acquisitions in the Past Five Years
Table 39. Monoclonal Antibody for Multiple Myeloma New Entrants and Expansion Plans
Table 40. Global Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) by Type (2016-2021)
Table 41. Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Type (2016-2021)
Table 42. Global Monoclonal Antibody for Multiple Myeloma Revenue Forecast by Type (2021-2026)
Table 43. Global Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2021)
Table 44. Global Monoclonal Antibody for Multiple Myeloma Revenue Forecast by Application (2021-2026)
Table 45. North America Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2021) & (USD Million)
Table 46. North America Monoclonal Antibody for Multiple Myeloma Revenue by Type (2021-2026) & (USD Million)
Table 47. North America Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2021) & (USD Million)
Table 48. North America Monoclonal Antibody for Multiple Myeloma Revenue by Application (2021-2026) & (USD Million)
Table 49. North America Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2021) & (USD Million)
Table 50. North America Monoclonal Antibody for Multiple Myeloma Revenue by Country (2021-2026) & (USD Million)
Table 51. Europe Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2021) & (USD Million)
Table 52. Europe Monoclonal Antibody for Multiple Myeloma Revenue by Type (2021-2026) & (USD Million)
Table 53. Europe Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2021) & (USD Million)
Table 54. Europe Monoclonal Antibody for Multiple Myeloma Revenue by Application (2021-2026) & (USD Million)
Table 55. Europe Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2021) & (USD Million)
Table 56. Europe Monoclonal Antibody for Multiple Myeloma Revenue by Country (2021-2026) & (USD Million)
Table 57. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2021) & (USD Million)
Table 58. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Type (2021-2026) & (USD Million)
Table 59. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2021) & (USD Million)
Table 60. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Application (2021-2026) & (USD Million)
Table 61. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Region (2016-2021) & (USD Million)
Table 62. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Region (2021-2026) & (USD Million)
Table 63. South America Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2021) & (USD Million)
Table 64. South America Monoclonal Antibody for Multiple Myeloma Revenue by Type (2021-2026) & (USD Million)
Table 65. South America Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2021) & (USD Million)
Table 66. South America Monoclonal Antibody for Multiple Myeloma Revenue by Application (2021-2026) & (USD Million)
Table 67. South America Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2021) & (USD Million)
Table 68. South America Monoclonal Antibody for Multiple Myeloma Revenue by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Type (2016-2021) & (USD Million)
Table 70. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Type (2021-2026) & (USD Million)
Table 71. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Application (2016-2021) & (USD Million)
Table 72. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Application (2021-2026) & (USD Million)
Table 73. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Country (2016-2021) & (USD Million)
Table 74. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Monoclonal Antibody for Multiple Myeloma Picture
Figure 2. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Type in 2020
Figure 3. Elotuzumab
Figure 4. Daratumumab
Figure 5. Siltuximab
Figure 6. Dacetuzumab
Figure 7. Rituximab
Figure 8. Other
Figure 9. Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application in 2020
Figure 10. Hospital Picture
Figure 11. Drug Center Picture
Figure 12. Clinic Picture
Figure 13. Other Picture
Figure 14. Global Monoclonal Antibody for Multiple Myeloma Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global Monoclonal Antibody for Multiple Myeloma Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Region (2016-2026)
Figure 17. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Region in 2020
Figure 18. North America Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Monoclonal Antibody for Multiple Myeloma Market Drivers
Figure 24. Monoclonal Antibody for Multiple Myeloma Market Restraints
Figure 25. Monoclonal Antibody for Multiple Myeloma Market Trends
Figure 26. Bristol Myers Squibb Recent Developments and Future Plans
Figure 27. Abbvie Recent Developments and Future Plans
Figure 28. Janssen Biotech Recent Developments and Future Plans
Figure 29. Karyopharm Therapeutics Recent Developments and Future Plans
Figure 30. PDL BioPharma Recent Developments and Future Plans
Figure 31. Roche Recent Developments and Future Plans
Figure 32. Seattle Genetics Recent Developments and Future Plans
Figure 33. Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Players in 2020
Figure 34. Monoclonal Antibody for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Monoclonal Antibody for Multiple Myeloma Revenue Market Share in 2020
Figure 36. Global Top 10 Players Monoclonal Antibody for Multiple Myeloma Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Type in 2020
Figure 39. Global Monoclonal Antibody for Multiple Myeloma Market Share Forecast by Type (2021-2026)
Figure 40. Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Application in 2020
Figure 41. Global Monoclonal Antibody for Multiple Myeloma Market Share Forecast by Application (2021-2026)
Figure 42. North America Monoclonal Antibody for Multiple Myeloma Sales Market Share by Type (2016-2026)
Figure 43. North America Monoclonal Antibody for Multiple Myeloma Sales Market Share by Application (2016-2026)
Figure 44. North America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Country (2016-2026)
Figure 45. United States Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Monoclonal Antibody for Multiple Myeloma Sales Market Share by Type (2016-2026)
Figure 49. Europe Monoclonal Antibody for Multiple Myeloma Sales Market Share by Application (2016-2026)
Figure 50. Europe Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Country (2016-2026)
Figure 51. Germany Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Region (2016-2026)
Figure 59. China Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Monoclonal Antibody for Multiple Myeloma Sales Market Share by Type (2016-2026)
Figure 66. South America Monoclonal Antibody for Multiple Myeloma Sales Market Share by Application (2016-2026)
Figure 67. South America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Monoclonal Antibody for Multiple Myeloma Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Monoclonal Antibody for Multiple Myeloma Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source

---